Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041)-Reference-Cited by-同舟云学术

Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041)

Published:2023-05 Issue: Volume:184 Page:1-9
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Fasching Peter A.^ORCID,Hein Alexander^ORCID,Kolberg Hans-Christian^ORCID,Häberle Lothar,Uhrig Sabrina,Rübner Matthias^ORCID,Belleville Erik,Hack Carolin C.,Fehm Tanja N.,Janni Wolfang,Hartmann Arndt,Erber Ramona^ORCID,Theuser Anna-Katharin,Brucker Sara Y.^ORCID,Hartkopf Andreas D.^ORCID,Untch Michael

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference23 articles.

1. Pembrolizumab for early triple-negative breast cancer;Schmid;N Engl J Med,2020

2. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial;Loibl;Lancet Oncol,2018

3. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial;Untch;Lancet Oncol,2016

4. KEYNOTE-522: phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC;Schmid;Ann Oncol,2021

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolving immunotherapeutic solutions for triple-negative breast carcinoma;Cancer Treatment Reviews;2024-11

2. Comparative effects of proton and photon irradiation on the molecular and cellular profiles of triple-negative breast cancer: the crucial impact of VEGFC on tumor microenvironment remodeling;2024-08-19

3. Neoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel in patients with early triple-negative breast cancer (NeoTENNIS): a single-arm, phase II study;eClinicalMedicine;2024-08

4. A review concerning the breast cancer-related tumour microenvironment;Critical Reviews in Oncology/Hematology;2024-07

5. Incidence of thyroid dysfunction caused by immune checkpoint inhibitors combined with chemotherapy: A systematic review and meta-analysis;International Immunopharmacology;2024-05